EUVIMEDEUVIMED entdecken
Crossref

The utility of H2 receptor antagonists in preventing infusion‐related reactions to paclitaxel chemotherapy

Corey Tsang iD, Jessica Robinson, Paul F Wheatley-Price, Stephanie Y Brule, Sara M Moore

Cancer · 2023

DOI: 10.1002/cncr.35006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Corey Tsang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, The Ottawa Hospital, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Paclitaxel, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paclitaxel has a risk of infusion‐related reactions (IRRs) and despite no prospective evidence, is often given with premedication including a corticosteroid, H1 antagonist, and H2 antagonist (H2RA). Backorders impacted the supply of intravenous H2RAs at our center, and it was removed as routine premedication. The authors compared the incidence of IRR in patients treated without H2RA to patients receiving standard H2RA premedication.

Methods

The authors reviewed outpatients starting paclitaxel at the Ottawa Hospital from December 2019 to October 2021. Two cohorts were created: patients treated without H2RA premedication (intervention), and those receiving standard H2RA (control). Demographics, treatment, and IRR information were collected retrospectively. Primary end point was rate of grade ≥2 IRRs during first two doses of paclitaxel.

Results

A total of 182 patients were treated without H2RA premedication, compared to 184 control patients treated during non‐backorder periods. Baseline characteristics included: median age, 63 years; 86% female; and primary tumor 52% breast/24% gynecologic/10% gastric/esophageal/8% lung/6% other. There were no significant differences between cohorts in baseline characteristics. There was no difference in the rate of grade ≥2 IRR between cohorts; 12.1% (22 of 182; 95% confidence interval [CI], 7.7%–17.7%) for patients treated without H2RA, and 15.1% (28 of 185; 95% CI, 10.3%–21.1%) for control patients. The rate of grade ≥3 IRRs were also similar, 4.4% in intervention cohort versus 3.8% in control cohort.

Conclusions

The removal of H2RAs from premedication for paclitaxel did not result in an increased incidence of IRRs. The use of H2RAs in preventing IRRs to paclitaxel should be re‐evaluated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelDrug-Related Side Effects and Adverse ReactionsHumansFemaleMiddle AgedMaleRetrospective StudiesHistamine H2 AntagonistsPremedication

Stichwörter der Autor:innen

histamine-2 antagonistinfusion-related reactionpaclitaxelpremedication

Substanzen

PaclitaxelHistamine H2 Antagonists

Autor:innen und Institutionen

  • Pharmacy Department, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • School of Pharmaceutical Sciences, University of Ottawa, Ottawa, Ontario, Canada.
  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

ORCID-Profile: Corey Tsang

Zitieren

APA

Tsang, C., Robinson, J., Wheatley-Price, P. F., Brule, S. Y., & Moore, S. M. (2023). The utility of H2 receptor antagonists in preventing infusion‐related reactions to paclitaxel chemotherapy. Cancer. https://doi.org/10.1002/cncr.35006

Vancouver

Tsang C, Robinson J, Wheatley-Price PF, Brule SY, Moore SM. The utility of H2 receptor antagonists in preventing infusion‐related reactions to paclitaxel chemotherapy. Cancer. 2023. doi:10.1002/cncr.35006

BibTeX
@article{Tsang2023,
  author = {Tsang, Corey and Robinson, Jessica and Wheatley-Price, Paul F and Brule, Stephanie Y and Moore, Sara M},
  title = {The utility of H2 receptor antagonists in preventing infusion‐related reactions to paclitaxel chemotherapy},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.35006}
}
Kostenlos starten →